Context Therapeutics Files 8-K Under 'Other Events'

TL;DR

CTX: 8-K filed 10/20 for 10/17 event. Details TBD.

AI Summary

Context Therapeutics Inc. filed an 8-K on October 20, 2025, reporting an event on October 17, 2025. The filing is categorized under 'Other Events' and provides no specific details about the nature of the event in the provided text.

Why It Matters

This filing indicates a material event has occurred for Context Therapeutics Inc., requiring disclosure to investors, though the specific nature of the event is not detailed in this excerpt.

Risk Assessment

Risk Level: medium — The filing is an 8-K under 'Other Events', which suggests a material development, but the lack of specific details makes it difficult to assess the immediate risk.

Key Players & Entities

• Context Therapeutics Inc. (company) — Registrant
• October 17, 2025 (date) — Earliest event date
• October 20, 2025 (date) — Filing date
• 2001 Market Street, Suite 3915, Unit #15 Philadelphia, Pennsylvania 19103 (address) — Principal executive offices

FAQ

Key Financial Figures

• $0.001 — mon Stock CNTX The Nasdaq Stock Market $0.001 par value per share Indicate by check
• $1.00 — maintain a minimum closing bid price of $1.00 per share for 30 consecutive business d

Filing Documents

• cntx-20251017.htm (8-K) — 22KB
• 0001628280-25-045513.txt ( ) — 146KB
• cntx-20251017.xsd (EX-101.SCH) — 2KB
• cntx-20251017_lab.xml (EX-101.LAB) — 24KB
• cntx-20251017_pre.xml (EX-101.PRE) — 14KB
• cntx-20251017_htm.xml (XML) — 3KB

01 Other Events

Item 8.01 Other Events. As previously disclosed by Context Therapeutics Inc. (the "Company") on that certain Current Report on Form 8-K filed on February 28, 2025 with the U.S. Securities and Exchange Commission (the "SEC"), on February 27, 2025, the Company received written notice (the "Notification Letter") from The Nasdaq Stock Market LLC ("Nasdaq") stating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Rule") because the Company's common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The Notification Letter provided the Company an initial 180 calendar day period, or until August 26, 2025, in which to regain compliance, pursuant to Nasdaq Listing Rule 5810(c)(3)(A). As previously disclosed by the Company on that certain Current Report on Form 8-K filed on September 2, 2025 with the SEC, on August 28, 2025, the Company received further written notice from Nasdaq informing the Company that Nasdaq granted the Company an additional 180 calendar days, or until February 23, 2026, to regain compliance with the Minimum Bid Price Rule. On October 17, 2025, the Company received a letter from Nasdaq notifying the Company that, for the last 10 consecutive business days, the closing bid price of the Company's common stock has been at $1.00 per share or greater and that the Company has regained compliance with the Minimum Bid Price Rule. Accordingly, Nasdaq considers the matter closed.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: October 20, 2025 Context Therapeutics Inc. By: /s/ Martin A. Lehr Name: Martin A. Lehr Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR